Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder

Endocrine Journal

Volumn 60, Issue 3, 2013, Pages 275-281

  Nakamura, Aya ^a   Watanabe, Masami ^a,b   Sugimoto, Morito ^a   Sako, Tomoko ^a   Mahmood, Sabina ^b   Kaku, Haruki ^a,b   Nasu, Yasutomo ^a,b   Ishii, Kazushi ^a   Nagai, Atsushi ^c   Kumon, Hiromi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Dose response analysis; Estradiol; Female to male; Gender identity disorder; Testosterone

Indexed keywords

ESTRADIOL; TESTOSTERONE; TESTOSTERONE ENANTATE;

ACNE; ADULT; AGE; AGGRESSION; ANDROGEN THERAPY; ARTICLE; BLOOD CLOTTING PARAMETERS; BODY WEIGHT; CLINICAL EVALUATION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; ESTRADIOL BLOOD LEVEL; FACIAL HAIR; FEMALE; GENDER IDENTITY DISORDER; HAIR; HEMATOCRIT; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; SEBORRHEA; SIDE EFFECT; SLEEP DISORDERED BREATHING; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; VOICE CHANGE;

DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; GENDER IDENTITY; HAIR; HORMONE REPLACEMENT THERAPY; HUMANS; INJECTIONS, INTRAMUSCULAR; JAPAN; MALE; MENSTRUATION; TESTOSTERONE; TIME FACTORS; TRANSGENDERED PERSONS; TRANSSEXUALISM; VOICE;

EID: 84875907721     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0319     Document Type: Article

References (11)

1. Bullough VL (1975) Transsexualism in history. Arch Sex Behav 4: 561-571.
2. Shahidi NT (2001) A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 23: 1355-1390.
3. Moore E, Wisniewski A, Dobs A (2003) Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 88: 3467-3473.
4. Hembree WC (2011) Guidelines for pubertal suspension and gender reassignment for transgender adolescents. Child Adolesc Psychiatr Clin N Am 20: 725-732.
5. Gooren LJ, Giltay EJ (2008) Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med 5: 765-776.
6. Jacobeit JW, Gooren LJ, Schulte HM (2009) Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Eur J Endocrinol 161: 795-798.
7. Okabe N, Sato T, Matsumoto Y, Ido Y, Kuroda S, et al. (2008) Clinical characteristics of patients with gender identity disorder at a Japanese gender identity disorder clinic. Psychiatry Res 157: 315-318.
8. Terada S, Matsumoto Y, Sato T, Okabe N, Uchitomi Y, et al. (2012) School refusal by patients with gender identity disorder. Gen Hosp Psychiatry 34: 299-303.
9. Watanabe M, Nagai A, Kusumi N, Tsuboi H, Kumon H, et al. (2005) Minimal invasiveness and effectivity of subinguinal microscopic varicocelectomy: a comparative study with retroperitoneal high and laparoscopic approaches. Int J Urol 12: 892-898.
10. Kaku H, Saika T, Tsushima T, Ebara S, Kumon H, et al. (2006) Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 66: 439-444.
11. Ebert T, Jockenhövel F, Morales A, Shabsigh R (2005) The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel. Eur Urol 47: 137-146.